ContraVir Pharmaceuticals Inc (CTRV) was Initiated by Maxim Group to “Buy” and the brokerage firm has set the Price Target at $4. Maxim Group advised their investors in a research report released on May 6, 2016.
ContraVir Pharmaceuticals Inc opened for trading at $0.96 and hit $0.99 on the upside on Wednesday, eventually ending the session at $0.98, with a gain of 2.08% or 0.02 points. The heightened volatility saw the trading volume jump to 71,493 shares. Company has a market cap of $27 M.
In a different news, on Feb 18, 2016, James Sapirstein (CEO) purchased 10,000 shares at $1.00 per share price.
ContraVir Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused primarily on the development of virology drugs to treat diseases of unmet needs such as herpes zoster and hepatitis B (HBV). The Company is developing targeted antiviral therapies with two drug candidates in clinical studies. The Company’s FV-100 is an orally available small molecule nucleoside analogue pro-drug of CF-1743 that it is developing for the treatment of herpes zoster which is an infection caused by the reactivation of varicella zoster virus or VZV. Its FV-100 which is in Phase III trials is being developed for the treatment of herpes zoster or shingles and shingle pain. The Company is also developing CMX157 a highly potent analog of the antiviral drug tenofovir DF (Viread). Its CMX157 is a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. It has completed a Phase I clinical trial.